Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease

Advances in Chronic Kidney Disease

Volumn 21, Issue 3, 2014, Pages 281-286

  Yamout, Hala ^a   Lazich, Ivana ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hypertension; Kidney; Nephropathy

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NISOLDIPINE; RAMIPRIL; RENIN; RENIN INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HORMONE INHIBITION; HUMAN; HYPERTENSION; MEDICATION THERAPY MANAGEMENT; MICROALBUMINURIA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DRUG EFFECTS; HYPERTENSION, RENAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION, RENAL; RENIN-ANGIOTENSIN SYSTEM;

EID: 84899500128     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.03.005     Document Type: Review

References (48)

1. de Boer I.H., Rue T.C., Hall Y.N., Heagerty P.J., Weiss N.S., Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. J Am Med Assoc 2011, 305:2532-2539.
2. Fox C.S., Matsushita K., Woodward M., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012, 380:1662-1673.
3. Tonelli M., Muntner P., Lloyd A., et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012, 380:807-814.
4. Mahmoodi B.K., Matsushita K., Woodward M., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012, 380:1649-1661.
5. Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25:199-201.
6. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
7. Brenner B.M., Cooper M.E., de Z.D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
8. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
9. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
10. Bakris G.L., Copley J.B., Vicknair N., Sadler R., Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641-1650.
11. Bakris G.L., Mangrum A., Copley J.B., Vicknair N., Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997, 29:744-750.
12. Estacio R.O., Coll J.R., Tran Z.V., Schrier R.W. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006, 19:1241-1248.
13. Estacio R.O., Jeffers B.W., Gifford N., Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(suppl 2):B54-B64.
14. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
15. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
16. Bakris G.L., Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich) 2002, 4:420-423.
17. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877-884.
18. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945.
19. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252-1256.
20. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 2002, 288:2421-2431.
21. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
22. Berl T., Hunsicker L.G., Lewis J.B., et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005, 16:2170-2179.
23. Wheeler D.C., Becker G.J. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. Kidney Int 2013, 83:377-383.
24. Taler S.J., Agarwal R., Bakris G.L., et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013, 62:201-213.
25. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
26. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
27. Bakris G.L., Oparil S., Purkayastha D., Yadao A.M., Alessi T., Sowers J.R. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2013, 15:92-100.
28. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
29. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369:1892-1903.
30. Bomback A.S., Kshirsagar A.V., Amamoo M.A., Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211.
31. Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30:418-424.
32. Weinberg J.M., Appel L.J., Bakris G., et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009, 169:1587-1594.
33. Van Buren P.N., Adams-Huet B., Nguyen M., Molina C., Toto R.D. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol 2014, 9:295-301.
34. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
35. Weber M.A., Bakris G.L., Jamerson K., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56:77-85.
36. Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173-1181.
37. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713.
38. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998, 317:713-720.
39. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
40. Upadhyay A., Earley A., Haynes S.M., Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011, 154:541-548.
41. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
42. Sarafidis P.A., Khosla N., Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007, 49:12-26.
43. Kalaitzidis R.G., Bakris G.L. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol 2012, 10:156-161.
44. Mancia G., Fagard R., Narkiewicz K., et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013, 31:1925-1938.
45. Ruggenenti P., Perna A., Loriga G., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005, 365:939-946.
46. Appel L.J., Wright J.T., Greene T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363:918-929.
47. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
48. Kalaitzidis R., Bakris G.L. Optimizing blood pressure and reducing proteinuria. Handbook of Chronic Kidney Disease Management 2011, 224-239. Lippincott, Williams & Wilkens, Philadelphia, PA. J. Daugirdas (Ed.).